On the varieties of conscious experiences: Altered Beliefs Under Psychedelics (ALBUS).
Neuroscience of consciousness – January 01, 2025
Source: PubMed
Summary
Psychedelics can both weaken and strengthen belief systems in the brain, similar to lucid dreaming states. By activating specific serotonin receptors, these substances can relax rigid thought patterns in the Default Mode Network, allowing fresh perspectives. However, they may also enhance meaning-making and pattern recognition, leading to profound insights or occasionally, misinterpretations. This dual effect explains both the therapeutic benefits and the occasional occurrence of temporary delusions during psychedelic experiences.
Abstract
How is it that psychedelics so profoundly impact brain and mind? According to the model of "Relaxed Beliefs Under Psychedelics" (REBUS), 5-HT2a agonism is thought to help relax prior expectations, thus making room for new perspectives and patterns. Here, we introduce an alternative (but largely compatible) perspective, proposing that REBUS effects may primarily correspond to a particular (but potentially pivotal) regime of very high levels of 5-HT2a receptor agonism. Depending on both a variety of contextual factors and the specific neural systems being considered, we suggest opposite effects may also occur in which synchronous neural activity becomes more powerful, with accompanying "Strengthened Beliefs Under Psychedelics" (SEBUS) effects. Such SEBUS effects are consistent with the enhanced meaning-making observed in psychedelic therapy (e.g. psychological insight and the noetic quality of mystical experiences), with the imposition of prior expectations on perception (e.g. hallucinations and pareidolia), and with the delusional thinking that sometimes occurs during psychedelic experiences (e.g. apophenia, paranoia, engendering of inaccurate interpretations of events, and potentially false memories). With "Altered Beliefs Under Psychedelics" (ALBUS), we propose that the manifestation of SEBUS vs. REBUS effects may vary across the dose-response curve of 5-HT2a signaling. While we explore a diverse range of sometimes complex models, our basic idea is fundamentally simple: psychedelic experiences can be understood as kinds of waking dream states of varying degrees of lucidity, with similar underlying mechanisms. We further demonstrate the utility of ALBUS by providing neurophenomenological models of psychedelics focusing on mechanisms of conscious perceptual synthesis, dreaming, and episodic memory and mental simulation.